Lara Cristina Rocha Alvarenga, Luiza Ferreira Rocha, Luis Mário Mendes de Medeiros, Nathália Ramos Lopes, Bráulio Brandão Rodrigues, Clara Braga dos Santos Azevedo, Daniela Cristina Tiago, Denis Masashi Sugita

Institution: Centro Universitário de Anápolis – UniEVANGÉLICA

Objective: Describe the prevalence of performing breast biopsy by the Unified Health System (SUS) in Brazil between 2009 and 2014. Methodology: The research is based on a retrospective and quantitative study with approach cross section held in the regions of Brazil between the years 2009 to 2014. The sample consisted of patients who underwent incisional biopsy, excisional, core biopsy and stereotactic needle. Data were obtained from the DATASUS system, secondary, in the database category in Cancer and Breast Information System (SISMAMA). There were used as variable regions of Brazil, satisfaction and exam type and year of procedure. Results: It was noted that between 2009 to2014, there were 102,871 biopsies in Brazil, with 66,118 of these core biopsy and only 3,335 of stereotactic type. Among the Brazilian regions that prevailed the procedure, cite the Southeast (58.62%) and Northeast (24.33%), followed by the southern regions (9.76%), Midwest (5.08%) and north (2.19%). Of the total of biopsies performed, 54,248 were made through imaging methods and only 809 procedures were classified as unsatisfactory. Finally, the year 2012 was one that presented more conduits (22,304) in contrast with 2009, which notified only 6,062 of them. Conclusion: It is concluded from the data that the mammary biopsies are mostly through core biopsy, a relatively simple method that does not require hospitalization of the patient. Still, the highest prevalence in the Southeast reflects the increased demand for health services and the largest professional availability for the exam. Finally, it was observed that breast biopsy is an effective procedure for the diagnosis of various diseases and is widely used by users of SUS in Brazil. Key word: breast cancer. Key word: breast cancer.